INTRODUCTION
Individual variations in response to a drug originate from different causes, such as genetic polymorphism and altered expression levels of drug target molecules (e.g. membrane receptors, nuclear receptors and enzymes), as well as those of drug-metabolizing enzymes and drug transporters [1] . To achieve the much-talkedabout 'personalized medicine', it is critically important that we understand the molecular mechanisms and functions underlying such variations in drug response.
Cancer is one of the gene-associated diseases, with multiple factors involved in its cause and progression [2] . Despite enormous costs and efforts spent on the development of cancer chemotherapies, anticancer drugs are often effective only in a relatively small proportion of cancer patients. It has long been recognized that the effectiveness of anticancer drugs can vary significantly among individual patients. Indeed, acquired and intrinsic drug resistance in cancer is the major obstacle to longterm, sustained patient response to chemotherapy.
There is accumulating evidence that active export of anticancer drugs from cancer cells is one of the major mechanisms of drug resistance. Several ATP-binding cassette (ABC) transporters underlie multidrug resistance in cancer cells by actively extruding the clinically administered chemotherapeutic drugs. Two major ABC transporters, ABCB1 (P-glycoprotein or MDR1) and ABCC1 (MRP1), have been well studied in terms of their structure Abbreviations used: ABC, ATP-binding cassette; BCRP, breast-cancer-resistant protein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HRP, horseradish peroxidase; MTT, bromo-3-(4,5-dimethyl-2-thiazoyl)-2,5-diphenyltetrazolium; RT, reverse transcription; SN-38, 7-ethyl-10-hydroxycamptothecin; SNP, single-nucleotide polymorphism. 1 To whom corrrespondence should be addressed (e-mail tishikaw@bio.titech.ac.jp).
and function in cancer drug resistance [3] [4] [5] [6] [7] [8] . In addition, a novel ABC transporter, breast-cancer-resistant protein (BCRP), has recently been discovered in doxorubicin-resistant breast-cancer cells [9] . The same transporter has also been found in human placenta [10] as well as in drug-resistant cancer cells selected by using mitoxantrone and DNA topoisomerase I inhibitors [11] [12] [13] [14] [15] [16] [17] [18] . The newly found ABC transporter protein is now named ABCG2 and is classified in the G-subfamily of human ABC transporter genes according to the new nomenclature. ABCG is a so-called 'half-transporter' bearing six transmembrane domains and one ATP-binding cassette. Overexpression of ABCG2 reportedly confers cancer-cell resistance to camptothecin-based anticancer drugs such as mitoxantrone, topotecan and 7-ethyl-10-hydroxycamptothecin (SN-38: active metabolite of irinotecan). SN-38-selected PC-6/ SN2-5H human lung-carcinoma cells were shown to overexpress ABCG2 with the decreased intracellular accumulation of SN-38 and its glucuronide metabolite. We have recently demonstrated that plasma-membrane vesicles prepared from those cells ATPdependently transported both SN-38 and SN-38-glucuronide, and our results strongly suggested that ABCG2 is involved in the active extrusion of SN-38 and its metabolite from cancer cells [19] .
To date, at least three variant forms of ABCG2 have been documented on the basis of amino acid moieties at position 482, which is close to the third transmembrane domain. The wild-type form of ABCG2 has an arginine at that position [10] , whereas other variants cloned from cancer cell lines [9, 13] have glycine and threonine at position 482. It is currently speculated that the substrate specificities of ABCG2 may differ among those variant forms [18, [20] [21] [22] . To elucidate the role of amino acid moieties at position 482 in the transport function, we have expressed each variant form of ABCG2 in HEK-293 cells and examined the substrate specificity of those variants. In the present study, we demonstrate that Arg 482 is critically involved in methotrexate transport mediated by ABCG2. Furthermore, we provide direct evidence that the ABCG2 protein functions as a homodimer bound via a cysteinyl disulphide bond(s).
EXPERIMENTAL

Cloning of human [Arg 482 ]ABCG2 cDNA
Human ABCG2 cDNA was cloned from mRNA of the MCF7/ BCRP clone-8 cell line [9] . Briefly, reverse transcription (RT)-PCR was carried out by using the SuperScript First-Strand Synthesis System (Invitrogen, Carlsbad, CA, U.S.A.) and the following specific primers: sense 5 -CTCTCCAGATGTCTTCC-AGT-3 and antisense 5 -ACAGTGTGATGGCAAGGGAAC-3 , where the primers were designed based on the ABCG2 cDNA sequences. The PCR reaction consisted of 30 cycles of 95
• C for 30 s, 58
• C for 30 s and 72
• C for 2 min, as previously described [23] . The resulting PCR product was inserted into the pCR2.1 TOPO vector (Invitrogen) and its sequences were analysed by automated DNA sequencing (TOYOBO Gene Analysis, Tokyo, Japan 
Cell culture
HEK-293 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10 % (v/v) heat-inactivated fetal-calf serum, penicillin (100 units/ml), and streptomycin (100 µg/ml) in a humidified atmosphere of 5 % CO 2 in air. The number of viable cells was determined in a haemocytometer by Trypan Blue dye exclusion. HEK-293 cells were transfected with the pcDNA3.1 vector carrying the ABCG2 cDNA (see Figure 1A below) and the LIPOFECTAMINE TM reagent (Invitrogen) according to the manufacturer's instruction. Single colonies resistant to G418 (Nacalai Tesque, Kyoto, Japan) were picked and subcultured. Selection of positive colonies was performed by immunoblotting, as described below.
Quantitative RT-PCR
Total RNA was extracted from cultured cells with the ISOGEN RNA extraction solution (WAKO Pure Chemical Industries, Ltd., Osaka, Japan) according to the manufacturer's protocol. cDNA was prepared from the extracted RNA in the reverse transcriptase reaction with SuperScript II RT (Invitrogen) and oligo(dT) primers according to the manufacturer's instructions. The transcriptome level of each ABC transporter was determined by quantitative PCR in a TaKaRa SmartCycler TM (TaKaRa Bio Inc., Shiga, Japan) with SYBR Green I (BioWhittaker Molecular Applications, Rockland, ME, U.S.A.) as a fluorescence indicator and the following specific primer sets for ABCG2, ABCC1, ABCC2, ABCC3, ABCC4, ABCC5 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH): ABCG2 (5 -GATCTCTC-ACCCTGGGGCTTGTGGA, 5 -TGTGCAACAGTGTGATGG-CAAGGGA), ABCC1 (5 -GCCCTTCCTGACAAGCTAGAC, 5 -CATATAGGCCCTGCAGTTCTGAC), ABCC2 (5 -AGGTG-GCTTGCAATTCGCCT, 5 -CCAATCTTCTCCATGCTACCG-ATGT), ABCC3 (5 -CTAGAGGCATCTTCTACGGGA, 5 -ATA-ACACTCAGTTGGGAATCGG), ABCC4 (5 -TCCCACTTGTC-ATCTTCTCTC, 5 -CAGCACTTTGTCGAACACAC), ABCC5 (5 -GTGGAGTTTGACACCCCATCGGTC, 5 -CCAATCCGG-AACTGCTGTGCGAAAG), GAPDH (5 -ACTGCCAACGTGT-CAGTGGTGGACCTGA; 5 -GGCTGGTGGTCCAGGGGTCT-TACTCCTT). PCR conditions for the detection of these transporters and GAPDH are summarized in Table 1 .
Immunofluorescence microscopy
Mock-and ABCG2-transfected HEK-293 cells were seeded on microscopic cover glasses and incubated under the abovementioned culture conditions overnight. Cells were fixed with 4 % (w/v) paraformaldehyde in PBS at room temperature. Thereafter, cell membranes were permeabilized by incubating them with 0.1 % Triton X-100 in PBS at room temperature for 5 min. Cells were then treated with the BXP-21 antibody (1:20 dilution; Signet Laboratories Inc., Dedham, MA, U.S.A.) as the first antibody and subsequently with the fluorescent-dye-Cy3-conjugated anti-mouse IgG antibody (1:500 dilution; Jackson ImmunoResearch Laboratories, Inc., Baltimore, MA, U.S.A.). The immunofluorescence of HEK-293 cells was detected with a confocal laser-scanning fluorescence microscope IX70/Fluoview (Olympus; Tokyo, Japan).
Preparation of plasma-membrane vesicles from HEK-293 cells
HEK-293 cells (approx. 2 ×10
9 cells) were harvested by centrifugation and suspended in 100 ml of ice-cold PBS. After centrifugation at 500 g for 5 min, the cell pellet was diluted 40-fold with a hypotonic buffer [0.5 mM sodium phosphate (pH 7.0)/ 0.1 mM EGTA] and homogenized with a Potter-Elvehjem homogenizer. After centrifugation at 9100 g, the resulting supernatant was centrifuged at 100 000 g for 30 min, and the resulting pellet was suspended in 250 mM sucrose containing 10 mM Tris/ HCl, pH 7.4. The crude membrane fraction was layered over 38 % (w/v) sucrose solution and centrifuged at 100 000 g for 30 min. The turbid layer at the interface was collected, suspended in 250 mM sucrose containing 10 mM Tris/HCl, pH 7.4, and centrifuged at 100 000 g for 30 min. The membrane fraction was collected and resuspended in a small volume (150-250 µl) of 250 mM sucrose containing 10 mM Tris/HCl, pH 7.4. After the measurement of protein concentration by the BCA (bicinchoninic acid) Protein Assay Kit (Pierce, Rockford, IL, U.S.A.), the membrane solution was stored at − 80
• C until used.
Detection of ATP-dependent transport of [ 3 H]methotrexate
Frozen stocked membrane was thawed quickly at 37
• C, and vesicles were formed by passing the suspension through a 27-gauge needle. The standard incubation medium contained plasmamembrane vesicles (30 or 60 µg of protein), 500 µM [3 ,5 ,7 -3 H]methotrexate (Amersham Biosciences), 250 mM sucrose, 10 mM Tris/HCl, pH 7.4, 10 mM MgCl 2 , 1 mM ATP, 10 mM creatine phosphate and 100 µg/ml creatine kinase in a final volume of 110 µl. The reaction was started by adding [ 3 H]methotrexate to the incubation medium. The reaction was carried out at 37
• C, and the amount of [ 3 H]methotrexate incorporated into the vesicles was measured by a rapid-filtration technique previously described [24] .
Gel electrophoresis and detection of ABCG2 protein
Expression of ABCG2 in HEK-293-cell membranes was determined by immunoblotting with BXP-21 (Signet), a specific antibody to human ABCG2 where membrane proteins were pretreated with or without mercaptoethanol (more details are given in the Results section). Briefly, proteins of the isolated plasma membrane were separated by electrophoresis on SDS/7.5 %-(w/v)-polyacrylamide slab gels, and the proteins were electroblotted on to Hy-bond ECL R (enhanced chemiluminescence) nitrocellulose membranes (Amersham Biosciences). Immunoblotting was performed by using BXP-21 (1:250 dilution) as the first antibody and an anti-mouse IgG-horseradish peroxidase (HRP) conjugate (Cell Signaling Technology, Beverly, MA, U.S.A.) (1:3000 dilution) as the secondary antibody. HRPdependent luminescence was developed by using Western Lighting Chemiluminescent Reagent Plus (PerkinElmer Life Sciences, Boston, MA, U.S.A.) and detected with a Lumino Imaging Analyzer FAS-1000 (Toyobo, Osaka, Japan).
Profiling of drug resistance of ABCG2-overexpressing HEK-293 cells
A growth inhibition (IC 50 ) assay was performed by seeding HEK-293 cells at a density of 1000-2000 cells/well in 96-well plates containing the culture medium. After 24 h, mitoxantrone or methotrexate was added to the culture medium at different concentrations, and cells were further incubated with the drug in a humidified tissue-culture chamber (37 • C, 5 % CO 2 ) for 72 h. Surviving cells were detected by the bromo-3-(4,5-dimethyl-2-thiazoyl)-2,5-diphenyltetrazolium (MTT) assay [25] . Briefly, 20 µl of MTT solution (5 mg/ml) was added to the culture medium, and cells were incubated for 4 h at 37
• C. Thereafter, the culture medium was removed and cells were dissolved in 200 µl of DMSO. The absorbance of formazan, a metabolite of MTT, in the resulting solution was photometrically measured at a test wavelength of 570 nm and at a reference wavelength of 630 nm in a Model 550 microplate reader (Bio-Rad, Hercules, CA, U.S.A.). IC 50 values were calculated from dose-response curves (i.e. cell survival versus drug concentration) obtained in multi-replicated experiments.
RESULTS
Expression of ABCG2 variants in HEK-293 cells
Three variant forms (i.e., Arg 482 , Gly 482 , and Thr 482 ) of human ABCG2 were expressed in HEK-293 cells by transfection with the pcDNA3.1 vector carrying the cDNA ( Figure 1A ). mRNA and protein levels of ABCG2 were detected by quantitative RT-PCR and Western blotting respectively; the mRNA levels of Arg 482 , Gly 482 and Thr 482 variants in HEK-293 cells are shown in Figure 1(B) . The parental HEK-293 cell line endogenously expressed ABCC1, ABCC2, ABCC4 and ABCC5, and the mRNA levels of ABCC3 and ABCG2 were below the detection limit. Similar expression profiles were observed in mock-transfected HEK-293 cells. On the other hand, in the Arg 482 -, Gly 482 -or Thr 482 -variant-transfected cells, mRNA levels of ABCG2 were significantly enhanced, corresponding to 13-20 % of the mRNA level of GAPDH. The expression levels of other ABC transporters, i.e., ABCC1, ABCC2, ABCC3, ABCC4 and ABCC5, were unchanged in these cells.
Western blotting ( Figure 1C ) revealed that the three variant forms of ABCG2 were also highly expressed at the protein level. In this experiment, membrane proteins were treated with mercaptoethanol prior to SDS/PAGE, so that one single band was detected with the BXP-21 antibody at an apparent molecular mass of 70 kDa. Mock-transfected HEK-293 cells, as the negative control, did not show any immunological reaction. (results not shown). On the other hand, no immunofluorescence was detected in mock-transfected HEK-293 cells as the negative control ( Figure 2B ). Thus it is proven that those three ABCG2 variants were expressed predominantly in the plasma membrane of HEK-293 cells. 
Drug-resistant profile of ABCG2-transfected HEK-293 cells
ATP-dependent transport of methotrexate by [Arg 482 ]ABCG2
The function of Arg 482 , Gly 482 and Thr 482 variants was examined by using plasma-membrane vesicles prepared from HEK-293 cells overexpressing those variants. Figure 4 depicts the time courses of methotrexate transport into plasma-membrane vesicles in the presence or absence of ATP. As previously described [24] , the ATP concentration was maintained at constant levels for a period sufficient for measurement (at least 20 min) with the creatine Figure 5 (A) demonstrates a relationship between the methotrexate concentration and the rate of ATP-dependent transport. On the basis of this result, the apparent K m value for methotrexate was calculated to be 5.7 mM. In addition, as shown in Figure 5 (B), ATP-dependent methotrexate transport mediated by [Arg 482 ]ABCG2 was inhibited by doxorubicin, mitoxantrone and rhodamine 123 at a concentration of 500 µM. In contrast, S-octylglutathione, which is a strong and competitive inhibitor for the GS-X (ATP-dependent glutathione-S-conjugate export) pump, e.g., ABCC1 and ABCC2 [24] , had a minimal inhibitory effect ( Figure 5B ).
Existence of ABCG2 as a homodimer in the plasma membrane
As shown in Figure 1(C) , ABCG2 was detected as one single band at a molecular mass of 70 kDa under reducing conditions. On the other hand, without mercaptoethanol treatment, ABCG2 exhibited a molecular mass of 140 kDa. shifted to 70 kDa on Western-blotting analysis ( Figure 6A ). This phenomenon was not unique for the Arg 482 variant, since similar molecular-mass shifts were observed for the Gly 482 and Thr 482 variants as well (results not shown). These results suggest that ABCG2 exists in the plasma membrane as a homodimer bound through cysteinyl disulphide bond(s). It is noteworthy that ATP-dependent methotrexate transport was little affected by mercaptoethanol treatment, in spite of the breakage of the interpeptide disulphide bonds ( Figure 6B ). In the present study, we have established HEK-293 cell lines that overexpress three variant forms of human ABCG2 (Figures 1  and 2 (Figure 4 ). The present study is the first report providing direct evidence that ABCG2 is able to transport methotrexate. Our finding strongly suggests that the Arg 482 close to the third transmembrane domain is a critical amino acid residue involved in the substrate specificity of ABCG2. Since the arginine residue is positively charged under physiological conditions, it is likely that its positive charge is a prerequisite for interactions between the active site of ABCG2 and anionic substrates such as methotrexate. However, as indicated by the weak inhibition by S-octylglutathione ( Figure 5B ), structural factors may also be important for the substrate recognition besides the negative charge. In fact, methotrexate transport was much more strongly inhibited by the glutathione conjugate of mitomycin C than by Soctylglutathione (H. Mitomo and T. Ishikawa, unpublished work).
Previous studies [26, 27] have predicted the existence of energydependent transport systems for the methotrexate efflux from cells. Molecular cloning and functional expression of ABC transporters led to the identification of human ABCC1, ABCC2, ABCC3 and ABCC4 as methotrexate transporters [28] [29] [30] . These transporters belong to the C-subfamily of human ABC transporters and exhibit broad spectra of substrate specificity towards organic anions, including glutathione, glucuronide and sulphate conjugates, as well as nucleotide analogues [7, 8] . The K m values for these ABC transporters in respect of methotrexate were reportedly in the range 200-500 µM [28] [29] [30] . Whereas HEK-293 cells endogenously express ABCC1, ABCC2, ABCC4 and ABCC5 ( Figure 1B ), ABCG2 expression was predominantly enhanced by transfection with the exogenous cDNA ( Figures 1B  and 1C ). ABCG2 proteins were localized at the plasma membrane of HEK-293 cells (Figure 2 ). The K m value of ATP-dependent transport by [Arg 482 ]ABCG2 was estimated to be 5.7 mM for methotrexate ( Figure 5A ), approximately one order of magnitude greater than those reported for the above-mentioned ABCCsubfamily transporters.
Variant forms of ABCG2 and drug-resistance phenotypes
Recently, Volk et al. [22] suggested that overexpression of the wild-type ([Arg482]ABCG2) mediates methotrexate resistance. Since the mitoxantrone-selected MCF7/MX cell line was used in their study, actual molecular mechanisms underlying the crossresistance to mitoxantrone and methotrexate were not known. Our present study on ATP-dependent methotrexate transport mediated by [Arg 482 ]ABCG2 in part supports their hypothesis. Indeed, HEK-293 cells transfected with [Arg 482 ]ABCG2 were resistant to mitoxantrone ( Figure 3A) . However, [Arg 482 ]ABCG2-transfected cells did not exhibit significant resistance to methotrexate ( Figure 3B ). This may be explained by the high K m value (5.7 mM) of [Arg 482 ]ABCG2 in respect of methotrexate ( Figure 5A ). In addition, it is also true that the Arg 482 -varianttransfected cells grew approx. 20 % more slowly than the Gly 482 -and Thr 482 -variant-transfected cells, suggesting that overexpression of ABCG2 could result in an enhanced efflux of unknown, but physiologically important, substances from cells.
Until now, several acquired mutations were documented for ABCG2 cloned from drug-resistant cell lines [20, 31] . Drugresistant phenotypes vary among different cell lines expressing variant types of ABCG2. In fact, transfectants with the wildtype (Arg  482 ) were not resistant to topotecan [18] , whereas overexpression of the Gly 482 and Thr 482 variants conferred resistance to mitoxantrone, doxorubicin, daunorubicin and various camptothecin analogues, including topotecan [9, [14] [15] [16] . Furthermore, Gly 482 and Thr 482 variants mediated the efflux of rhodamine 123 and doxorubicin from cells; however, Arg 482 did not [20, 21] . These findings strongly suggest that arginine at position 482 has a critical role in the substrate specificity of ABCG2. The identification of mutations at 482 in ABCG2 may explain some discrepancies observed in the cross-resistance profiles of human cancer-cell lines. Likewise, one mutation 'hot spot' was identified at the same amino acid position 482 in mouse Abcg2 [32] . In the case of mouse Abcg2, variants of arginine, serine and methionine significantly affect the drug-resistance profile in cancer-cell lines [32] .
To examine the function of ABCG2 as a drug transporter, we have previously established ABCG2-overexpressing Sf9 [fall armyworm (Spodoptera frugiperda)] insect cells and tried to measure drug-induced ATPase activity [23] . However, because of a high activity of endogenous ATPase present in the plasma membrane, we were not able to accurately measure the druginduced ATPase activity of ABCG2 [23] .Özvegy et al.
[21] had a similar difficulty in the case of the [Arg 482 ]ABCG2. In this context, the vesicle transport system we used in the present study may offer a simple and practical tool to elucidate the substrate specificity and transport activity of human ABCG2 and its variants.
Homodimer formation of ABCG2
Since ABCG2 is an ABC half-transporter, it has been suspected that ABCG2 functions as a homodimer or heterodimer [15] . Most recently, using cross-linking reagents and specific antibodies, Litman et al. [33] provided evidence for the formation of an ABCG2 homodimer. In addition, Kage et al. [34] have recently established PA317 transfectants expressing c-Myc oncoprotein (Myc)-and haemagglutinin (HA)-epitope-tagged ABCG2 proteins, and they demonstrated that those hybrid proteins formed S-S homodimers. In the present study, by expressing native ABCG2 (without tag) in HEK-293 cells, we could provide more direct evidence that human ABCG2 exists in the plasma membrane as a homodimer bound through cysteinyl disulphide bond(s) (Figure 6 ). Treatment with mercaptoethanol decreased the apparent molecular mass of ABCG2 from 140 to 70 kDa ( Figure 6A ). It is noteworthy that ATP-dependent transport of methotrexate by [Arg 482 ]ABCG2 was little affected by mercaptoethanol treatment ( Figure 6B ). Thus disulphide-bond formation does not appear to be required for the transport function of ABCG2.
On the basis of the cDNA sequence, a total of 12 cysteine residues exist in the ABCG2 peptide. From a biochemical point of view, it may be interesting to study which cysteine residues participate in the disulphide-bond formation and how interpeptide disulphide bonds are formed in the cell. Furthermore, ABCG1, ABCG4, ABCG5 and ABCG8 have been hitherto identified as ABC half-transporters [35] , and it would be of interest to know whether those half-transporters also form homodimers or heterodimers via disulphide bonds as does ABCG2.
Concluding remarks
ABCG2 is expressed in human normal tissues such as placental syncytiotrophoblasts, the epithelium of the small intestine and colon, the liver canalicular membrane, and ducts and lobules of the breast [36] . In addition, expression of ABCG2 is detected in venous and capillary endothelium [36] . Furthermore, relatively high expression of ABCG2 is observed in approx. 30 % of acute-myeloid-leukaemia patients [37] and is correlated with an immature immunophenotype as determined by expression of the surface marker CD34 [38] . Not only expression levels, but also intrinsic genetic polymorphisms and acquired mutations of ABCG2, are suggested to affect the pharmacokinetic profile of drugs and thereby lead to individual variations in the drug response. Recently, two single-nucleotide polymorphisms (SNPs) leading to amino acid substitutions (i.e., Val 12 → Met and Gln 141 → Lys) for ABCG2 have been found in the Japanese population [39] . It is critically important to validate such SNPs and mutations by examining the actual function of the resulting gene products.
